Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Next leg of the uptick from recent low

<< Previous

Bullboard Posts

Next >>

Post by canadafanon Feb 19, 2024 9:42pm

398 Views

Post# 35888139

Next leg of the uptick from recent low

We hit a recent low a few weeks ago.
Since then a slow gradual ( very slow) climb.
Annoucement last week of yet another trial with Roche ( tripplng of standard of care & one complete recovery) all good stuff
I expect the next leg of Sp recovery this week. As we come closer to year end and Q2 update, they need a lot of things clarified.
I still sense they are in disaster recovery mode since Pancan backed away.
could the Roche additional trial be a continuaton of existing terms?
A buisness deal is needed and soon!